\u65f6\u95f4: 5\u670820\u65e5\u4e0b\u5348 4:45\u52308:00
\n\u5730\u5740: 11120 Roselle St, San Diego, CA 92121\uff0cUnion Station & Grand Central \u4f1a\u8bae\u5ba4
\n\u7f51\u4e0a\u62a5\u540d\uff1ahttp:\/\/sabpa.org\/html\/entresymp\/
\n\u4e94\u670817\u65e5\u524d\u7f51\u4e0a\u62a5\u540d\u514d\u8d39\uff01\uff01<\/p>\n
\u4e3b\u98981\uff1a Presentation #1: Reflections on My 3 year Mission as CEO of Ambit
\nAmbit Biosciences was founded in 2001, and merged with Daiichi Sankyo in November, 2014. Mr. Martino joined as CEO in November, 2011. As CEO, he guided the company\u2019s development from private to public to the merger, and oversaw the development of the company\u2019s lead asset, quizartinib, from Phase 2a to Phase 3. In his brief talk he will share reflections from his 3 year mission to develop the team, the pipeline and create value for shareholders.
\n\u6f14\u8bb2\u8005: Michael A. Martino, Former President & CEO of Ambit Biosciences
\nMike Martino was most recently President & CEO of Ambit Biosciences from Nov, 2011 to Jan, 2015, when he departed following the acquisition of Ambit by Daiichi Sankyo. Under his leadership, the Ambit team negotiated an amicable conclusion to a legacy collaborative development agreement with Astellas, concluded a Series E financing, completed the company\u2019s initial public offering, initiated a registrational Phase 3 trial for their lead drug, Quizartinib, and successfully closed the transaction with Daiichi Sankyo in Nov, 2014. Over Mr. Martino\u2019s tenure at Ambit, the team raised nearly $115M in new equity capital, not including the Daiichi Sankyo transaction. Previously, Mr. Martino also worked at Arzeda, a synthetic biology company, and was President & CEO of Sonus Pharmaceuticals, a publicly-traded company located in Bothell, WA.<\/p>\n
\u4e3b\u98982: Entrepreneurship as a Career Choice for Innovators
\nIn this talk, Dr. Li will tell the story of starting Nexcelom Bioscience, a life science tools company, and share how decisions have been made to start Nexcelom more than 10 years ago, and to develop Nexcelom into a global industry leader in cell counting and analysis, based on innovative image cytometry technologies.<\/p>\n
\u6f14\u8bb2\u8005: Peter Li, President of CEO at Nexcelom Bioscience
\nDr. Li is a co-founder and CEO of Nexcelom Bioscience, which develops and markets Cellometer\u00ae brand image-based cell counters and analysis systems and Celigo\u00ae Adherent Cell Cytometers for the life science market. Under Dr. Li\u2019s leadership, Nexcelom Bioscience was honored as an Inc 500 Company in 2009, as one of fastest growing private companies in America by Inc Magazine. Headquartered in the Boston area, Nexcelom Bioscience now serves pharmaceutical and biotechnology companies, and academic researchers, through its world-wide sites in Bethesda, San Diego, Manchester (UK) and Shanghai (China).<\/p>\n
Schedule:
\n4:45 to 6:00 pm: Reception and Networking
\n6:00 to 6:10 pm: Welcome and Announcements
\n6:10 to 7:00 pm: Presentation #1 and Q&A
\n7:00 to 7:45 pm: Presentation #2 and Q&A
\n7:45 to 8:00 pm: Networking<\/p>\n","protected":false},"excerpt":{"rendered":"
\u65f6\u95f4: 5\u670820\u65e5\u4e0b\u5348 4:45\u52308:00\uff0c\u5730\u5740: 11120 Roselle St, San Diego, CA 92121\uff0cUnion Station & Grand Central \u4f1a\u8bae\u5ba4
\n\u7f51\u4e0a\u62a5\u540d\uff1ahttp:\/\/sabpa.org\/html\/entresymp\uff0c\u4e94\u670817\u65e5\u524d\u7f51\u4e0a\u62a5\u540d\u514d\u8d39…..<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[34],"class_list":["post-154793","post","type-post","status-publish","format-standard","hentry","category-headline","tag-featured-2"],"_links":{"self":[{"href":"https:\/\/www.sandiegochinesepress.com\/press\/wp-json\/wp\/v2\/posts\/154793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sandiegochinesepress.com\/press\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sandiegochinesepress.com\/press\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sandiegochinesepress.com\/press\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sandiegochinesepress.com\/press\/wp-json\/wp\/v2\/comments?post=154793"}],"version-history":[{"count":0,"href":"https:\/\/www.sandiegochinesepress.com\/press\/wp-json\/wp\/v2\/posts\/154793\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.sandiegochinesepress.com\/press\/wp-json\/wp\/v2\/media?parent=154793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sandiegochinesepress.com\/press\/wp-json\/wp\/v2\/categories?post=154793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sandiegochinesepress.com\/press\/wp-json\/wp\/v2\/tags?post=154793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}